导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.82% | 3912/4773 |
| 近一周 | -2.92% | 3468/5458 |
| 近一月 | -2.56% | 1600/5421 |
| 近一季 | -4.77% | 2473/5205 |
| 近半年 | -10.88% | 3705/4920 |
| 近一年 | -17.94% | 3896/4361 |
| 近两年 | 36.73% | 2071/2954 |
| 近三年 | 21.32% | 1429/2253 |
| 成立以来 | 6.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.43% 4135/4961 |
-4.72% 3525/5312 |
- - |
- - |
| 2025 | 28.79% 1449/4813 |
5.38% 788/3635 |
12.23% 105/4076 |
17.89% 2408/4524 |
-7.63% 3820/4813 |
| 2024 | 13.77% 1109/3463 |
-2.79% 1431/2808 |
5.65% 191/3014 |
12.25% 2386/3129 |
-1.32% 1655/3463 |
| 2023 | -11.94% 1436/2656 |
-0.50% 1797/2280 |
-2.39% 587/2385 |
-5.80% 1378/2515 |
-3.74% 778/2655 |
| 2022 | -11.20% 232/2207 |
-10.87% 441/1919 |
5.37% 914/2016 |
-16.93% 1526/2113 |
13.83% 91/2208 |
| 2021 | -11.62% 1113/1822 |
2.93% 206/1255 |
4.43% 887/1330 |
-11.41% 1267/1466 |
-7.18% 1565/1822 |
| 2020 | 13.36% 803/1250 |
-14.51% 964/1028 |
11.63% 721/1067 |
5.37% 923/1164 |
12.74% 437/1184 |
| 2019 | 15.95% 688/1092 |
13.41% 697/754 |
-3.65% 403/804 |
-4.15% 761/850 |
10.70% 107/918 |
| 2018 | -19.39% 162/834 |
- - |
- - |
- - |
-10.26% 185/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发恒生中型股指数(LOF)A VS. 长安沪深300非周期A(740101) |